Real-world evidence on the efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori treatment in elderly patients

Table 5 Adverse events in each group, n (%)

Symptom	First-line, n = 250	Rescue, n = 130	Total, n = 380	Nonadherence due to AE	Failed in treatment
Skin rash	5 (2.0)	3 (2.3)	8 (2.1)	3	1
Abdominal pain	5 (2.0)	2 (1.5)	7 (1.8)	1	1
Abdominal discomfort	3 (1.2)	4 (3.1)	7 (1.8)	1	0
Diarrhea	4 (1.6)	1 (0.8)	5 (1.3)	0	0
Vomiting	3 (1.2)	0	3 (0.8)	0	0
Increased bowl movement	1 (0.4)	1 (0.8)	2 (0.5)	0	0
Abdominal distension	2 (0.8)	0	2 (0.5)	0	0
Constipation	1 (0.4)	1 (0.8)	2 (0.5)	0	0
Heartburn	1 (0.4)	0	1 (0.3)	0	0
Itchy skin	1 (0.4)	0	1 (0.3)	0	0
Nausea	1 (0.4)	0	1 (0.3)	0	0
Fever	1 (0.4)	0	1 (0.3)	0	0
Headache	0	1 (0.8)	1 (0.3)	0	0
Dizziness	1 (0.4)	0	1 (0.3)	0	0
Blood pressure decrease	1 (0.4)	0	1 (0.3)	0	0
Total AE	23 (9.2)	13 (10.0)	36 (9.5)	5	2
Adherence	247 (98.8)	128 (98.5)	375 (98.7)

AE: Adverse event.